Effectiveness of 3M Cavilon Advanced Skin Protectant in the Treatment of Moisture-associated Skin Damage in Hospitals
Launched by UNIVERSITY GHENT · Dec 11, 2023
Trial Information
Current as of May 30, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Problem statement:
Partial-thickness wounds (erosion/denudation of the epithelial and dermal layers of the skin) can occur due to prolonged exposure of moisture and irritants. Various sources of moisture can cause these superficial wounds called moisture-associated skin damage (MASD) which include wound exudate, bodily fluids from incontinence and effluent from stomas and fistulas. MASD can present as inflammation with or without erosion and even secondary infection. Partial-thickness denudation can be extremely painful and detrimental to the patient. Traditionally a wide array of treatmen...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient or their legally authorized representative signed informed consent.
- • The patient is expected to be in the study for the full duration of the trial.
- • The patient has partial thickness wounds caused by moisture (MASD) i.e.,
- • The patient has IAD category 2A or
- • Peri-wound MASD or
- • Peri-stomal MASD.
- Exclusion Criteria:
- • Patients with a known hypersensitivity or allergy to acrylate or cyanoacrylate.
- • The patient requires topical treatment due to a fungal, bacterial or viral infection in the study area.
- • Intertriginous dermatitis (most often a fungal infection is present).
- • Peri-fistula MASD (would usually require hospitalization).
- • The patient has any other local dermatological disease or skin condition interfering with this study.
- • Patients participating in another study with a known or implied effect on skin barrier function.
- • Patients who are receiving end-of-life care.
About University Ghent
University Ghent is a prestigious Belgian research institution renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a multidisciplinary approach, the university fosters collaboration among leading experts in various fields, ensuring rigorous study design and ethical standards. University Ghent is dedicated to exploring new therapeutic modalities and enhancing healthcare outcomes, making significant contributions to both local and global health landscapes. Its state-of-the-art facilities and emphasis on research excellence position it as a pivotal sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gent, , Belgium
Oudenaarde, , Belgium
Oostende, , Belgium
Patients applied
Trial Officials
Dimitri Beeckman, PhD
Principal Investigator
University Ghent
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported